Helix BioPharma Corp. (TSE:HBP – Get Rating) passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of C$0.20 and traded as high as C$0.23. Helix BioPharma shares last traded at C$0.21, with a volume of 10,050 shares trading hands.
The company has a debt-to-equity ratio of 2.60, a current ratio of 0.23 and a quick ratio of 0.20. The company’s 50 day moving average is C$0.20 and its 200 day moving average is C$0.26. The stock has a market cap of C$36.61 million and a price-to-earnings ratio of -3.23.
Helix BioPharma (TSE:HBP – Get Rating) last posted its earnings results on Tuesday, June 14th. The biopharmaceutical company reported C($0.01) earnings per share for the quarter. Sell-side analysts predict that Helix BioPharma Corp. will post -0.11 earnings per share for the current year.
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada.
- MarketBeat: Week in Review 6/13 – 6/17
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
- Palo Alto Networks: Pioneering AI in Cybersecurity
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.